IP Library Granted Patent US 10,751,346
Granted Patent B2
US 10,751,346 · App. 14/434,812 · Granted Aug 25, 2020

Pyrrolobenzodiazepine—anti-PSMA antibody conjugates

Inventors: Patricius Hendrikus Cornelis Van Berkel (Lausanne, CH); Philip Wilson Howard (London, GB)
Assignee: MEDIMMUNE LIMITED
A61K31/5517A61K45/06A61K47/6803A61K47/6869C07K16/18
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,751,346
App. No.
14/434,812
Granted
Aug 25, 2020
Kind
B2
Abstract

Conjugates of an antibody that binds to PSMA with PBD dimers.

Claims (11)

1. A conjugate of formula ConjE:

where Ab is an antibody that binds to PSMA, the antibody comprising a VH domain having the amino acid sequence according to SEQ ID NO: 3 and a VL domain having the amino acid sequence according to SEQ ID NO: 4; and wherein the drug loading of drugs to antibody is an integer from 1 to about 8.

2. The conjugate according to claim 1 wherein the antibody is an intact antibody.

3. The conjugate according to claim 1 wherein the antibody is humanised, deimmunised or resurfaced.

4. The conjugate according to claim 1 , wherein the drug loading of drugs to antibody is 1, 2, 3, or 4.

5. A mixture of conjugates according to claim 4 , wherein the average value of the drug loading of drugs to antibody is about 2 to about 5.

6. The conjugate according to claim 1 , wherein said conjugate comprises ConjE for use in treating a PSMA overexpressing cancer.

7. A pharmaceutical composition comprising the conjugate of claim 1 and a pharmaceutically acceptable diluent, carrier or excipient.

8. The pharmaceutical composition of claim 7 , further comprising a therapeutically effective amount of a chemotherapeutic agent.

9. A method of treating cancer comprising administering to a patient the pharmaceutical composition of claim 7 .

10. The method of claim 9 wherein the patient is administered a chemotherapeutic agent, in combination with the conjugate.

Assignments (6)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 11, 2019
From: ADC THERAPEUTICS SA
To: MEDIMMUNE LIMITED
Reel/Frame 050339/0591 →
CHANGE OF NAME Recorded Jan 31, 2018
From: ADC THERAPEUTICS SÀRL
To: ADC THERAPEUTICS S.A.
Reel/Frame 046119/0491 →
CORRECTIVE ASSIGNMENT TO CORRECT THE RECEIVING PARTY ADDRESS PREVIOUSLY RECORDED AT REEL: 039791 FRAME: 0157. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Sep 22, 2016
From: HOWARD, PHILIP WILSON
To: MEDIMMUNE LIMITED
Reel/Frame 040107/0618 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 20, 2016
From: VAN BERKEL, PATRICIUS HENDRIKUS CORNELIS
To: A.T. DEVELOPMENT SWITZERLAND SÀRL
Reel/Frame 039790/0855 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 20, 2016
From: A.T. DEVELOPMENT SWITZERLAND SÀRL
To: ADC THERAPEUTICS S.A.
Reel/Frame 039790/0982 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 20, 2016
From: HOWARD, PHILIP WILSON
To: MEDIMMUNE LIMITED
Reel/Frame 039791/0157 →